Copyright
©The Author(s) 2016.
World J Hepatol. Oct 18, 2016; 8(29): 1212-1221
Published online Oct 18, 2016. doi: 10.4254/wjh.v8.i29.1212
Published online Oct 18, 2016. doi: 10.4254/wjh.v8.i29.1212
Table 1 Demographics and characteristics of participants
n | % | |
Gender (n = 101) | ||
Male | 39 | 38.6 |
Female | 62 | 61.4 |
Age (yr) (n = 95) | ||
19-29 | 38 | 40.0 |
30-39 | 19 | 20.0 |
40-49 | 17 | 17.9 |
50-59 | 11 | 11.6 |
60-69 | 6 | 6.3 |
70-79 | 2 | 2.1 |
80-89 | 2 | 2.1 |
Education (n = 99) | ||
Illiterate | 3 | 3.0 |
Primary School Education | 3 | 3.0 |
Secondary School Graduate | 9 | 9.1 |
High School Education | 10 | 10.1 |
University Undergraduate Level | 50 | 50.5 |
Others | 24 | 24.2 |
Occupation (n = 99) | ||
Student | 15 | 15.2 |
Employed | 74 | 74.7 |
Unemployed | 7 | 7.1 |
Retired | 3 | 3 |
Table 2 The observed and estimated killer immunoglobulin receptor gene frequencies in the study participants
Inhibitory KIR | Non-inhibitory KIR | Pseudogene | |||||||||||||||
2DL1 | 2DL2 | 2DL3 | 2DL4 | 2DL5 | 3DL1 | 3DL2 | 3DL3 | 2DS1 | 2DS2 | 2DS3 | 2DS4 | 2DS5 | 3DS1 | 2DP1 | 3DP*001/002/004 | 3DP1*003 | |
OF | 99 | 56 | 84 | 100 | 42 | 96 | 100 | 100 | 40.6 | 55.4 | 46.5 | 95 | 34.7 | 41.6 | 99 | 17 | 100 |
KLF | 0.9 | 0.34 | 0.6 | 1 | 0.24 | 0.8 | 1 | 1 | 0.23 | 0.33 | 0.27 | 0.78 | 0.19 | 0.24 | 0.9 | 1 | 1 |
Table 3 Killer immunoglobulin receptor gene frequencies among study participants vaccinated against hepatitis B virus (protected and non-protected by hepatitis B vaccine) n (%)
KIR genes | Anti-HBsAg < 10 mIU/mL (n = 22) | Anti-HBsAg ≥ 10 mIU/mL (n = 52) | Test1 | OR (95%CI) | P value |
2DL2 | 14 (63.60) | 27 (51.90) | 0.858 | 0.62 (0.22-1.72) | 0.446 |
2DL3 | 18 (81.80) | 45 (86.40) | FET | 1.43 (0.37-5.48) | 0.723 |
2DL5A | 8 (36.40) | 13 (25.00) | 0.982 | 0.58 (0.20-1.70) | 0.4 |
2DL5B | 5 (22.70) | 19 (36.50) | 1.346 | 1.97 (0.62-6.16) | 0.289 |
2DS1 | 11 (50.00) | 19 (36.50) | 1.162 | 0.58 (0.21-1.58) | 0.31 |
2DS2 | 14 (63.60) | 26 (50.00) | 1.157 | 0.57 (0.21-1.59) | 0.318 |
2DS3 | 9 (40.90) | 23 (44.20) | 0.069 | 1.15 (0.42-3.15) | 0.804 |
2DS4*001/002 | 8 (36.40) | 20 (38.40) | 0.029 | 1.09 (0.39-3.072) | 1.00 |
2DS4*003/007 | 19 (86.40) | 41 (78.85) | FET | 0.59 (0.15-2.36) | 0.534 |
2DS5 | 10 (45.50) | 17 (32.60) | 1.087 | 0.58 (0.21-1.62) | 0.428 |
3DS1 | 11 (50.00) | 21 (40.40) | 0.582 | 0.68 (0.25-1.85) | 0.608 |
3DP*001/002/004 | 6 (27.30) | 9 (17.30) | FET | 0.56 (0.17-1.82) | 0.355 |
Table 4 Killer immunoglobulin receptor gene frequencies among study participants vaccinated against hepatitis B virus as compared to non-vaccinated subjects n (%)
KIR genes | Vaccinated (n = 74) | Non-vaccinated (n = 25) | Test1 | OR (95%CI) | P value |
2DL2 | 41 (55.40) | 15 (60.00) | 0.161 | 0.83 (0.33-2.082) | 0.436 |
2DL3 | 63 (85.10) | 20 (80.00) | 0.364 | 1.43 (0.44-4.62) | 0.374 |
2DL5A | 21 (28.40) | 4 (16.00) | 1.517 | 2.08 (0.64-6.79) | 0.168 |
2DL5B | 24 (32.40) | 5 (20.00) | 1.395 | 1.92 (0.64-5.73) | 0.178 |
2DS1 | 30 (40.50) | 10 (40.00) | 0.002 | 1.02 (0.41-2.58) | 0.577 |
2DS2 | 40 (54.10) | 15 (60.00) | 0.268 | 0.78 (0.31-1.97) | 0.39 |
2DS3 | 32 (43.20) | 14 (56.00) | 1.223 | 0.60 (0.24-1.49) | 0.191 |
2DS4*001/002 | 28 (37.80) | 11 (44.00) | 0.297 | 0.77 (0.31-1.94) | 0.376 |
2DS4*003/007 | 60 (81.10) | 22 (88.00) | FET | 0.58 (0.15-2.23) | 0.324 |
2DS5 | 27 (36.50) | 7 (28.00) | 0.597 | 1.47 (0.55-3.99) | 0.302 |
3DS1 | 32 (43.20) | 9 (36.00) | 0.246 | 1.35 (0.53-3.46) | 0.401 |
3DP*001/002/004 | 15 (20.30) | 2 (8.00) | FET | 2.92 (1.62-13.80) | 0.134 |
Table 5 The relationship between AA, AB and BB genotypes and the expression of killer immunoglobulin receptor genes among the study participants n (%)
KIR genes | AA (n = 44) | AB (n = 41) | BB (n = 16) | Test1 | P value |
2DL2 | 0 (0.00) | 41 (100.00) | 16 (100.00) | 101 | 0.00a |
2DL3 | 44 (100.00) | 41 (100.00) | 0 (0.00) | 101 | 0.00a |
2DL5A | 10 (22.70) | 10 (22.70) | 5 (31.25) | FET | 0.782 |
2DL5B | 1 (2.27) | 20 (24.39) | 8 (50.00) | FET | 0.00a |
2DS1 | 16 (36.30) | 18 (43.90) | 7 (43.75) | 0.579 | 0.749 |
2DS2 | 0 (0.00) | 40 (97.50) | 16 (100.00) | 97.051 | 0.00a |
2DS3 | 3 (6.80) | 30 (73.17) | 14 (87.50) | 50.38 | 0.00a |
2DS4*001/002 | 16 (36.40) | 19 (37.50) | 6 (37.50) | 0.952 | 0.621 |
2DS4*003/007 | 38 (86.40) | 31 (75.60) | 14 (87.50) | FET | 0.392 |
2DS5 | 14 (31.80) | 16 (39.00) | 5 (31.30) | 0.584 | 0.747 |
3DS1 | 18 (40.90) | 18 (43.90) | 6 (40.00) | 0.107 | 0.948 |
3DP*001/002/004 | 2 (4.50) | 10 (24.40) | 5 (31.30) | FET | 0.0006a |
Table 6 Killer immunoglobulin receptor gene expression and levels of anti-HBs among the vaccinated study participants n (%)
KIR genes | Group I1 (n = 36) | Group II2 (n = 16) | Group III3 (n = 15) | Group IV4 (n = 7) | Test5 | P value |
2DL2 | 17 (47.20) | 10 (62.50) | 11 (73.30) | 3 (42.90) | FET | 0.362 |
2DL3 | 31 (86.10) | 14 (87.50) | 12 (80.00) | 6 (85.70) | FET | 0.824 |
2DL5A | 9 (25.00) | 4 (25.00) | 4 (26.70) | 4 (57.10) | FET | 0.987 |
2DL5B | 9 (25.00) | 10 (62.50) | 4 (26.70) | 1 (14.30) | FET | 0.0236 |
2DS1 | 11 (30.60) | 8 (50.00) | 7 (46.70) | 4 (57.10) | FET | 0.530 |
2DS2 | 16 (44.40) | 10 (62.50) | 11 (73.30) | 3 (42.90) | FET | 0.270 |
2DS3 | 12 (33.30) | 11 (68.80) | 8 (53.30) | 1 (14.30) | 5.01 | 0.060 |
2DS4*001/002 | 15 (41.70) | 5 (31.30) | 6 (40.00) | 2 (28.60) | 0.568 | 0.920 |
2DS4*003/007 | 28 (77.80) | 13 (81.30) | 13 (86.70) | 6 (85.70) | FET | 0.860 |
2DS5 | 11 (30.60) | 6 (37.50) | 6 (40.00) | 3 (42.90) | 0.846 | 0.850 |
3DS1 | 14 (38.90) | 7 (43.80) | 7 (46.70) | 6 (85.70) | FET | 0.960 |
2DL4 | 36 (100.00) | 16 (100.00) | 15 (100.00) | 4 (57.10) | 0.258 | 0.970 |
3DP*001/002/004 | 8 (22.20) | 1 (6.30) | 4 (26.70) | 1 (14.30) | FET | 0.420 |
- Citation: Melhem NM, Mahfouz RA, Kreidieh K, Abdul-Khalik R, El-Khatib R, Talhouk R, Musharrafieh U, Hamadeh G. Potential role of killer immunoglobulin receptor genes among individuals vaccinated against hepatitis B virus in Lebanon. World J Hepatol 2016; 8(29): 1212-1221
- URL: https://www.wjgnet.com/1948-5182/full/v8/i29/1212.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i29.1212